Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 6/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | GCG | P01275 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24118326 | 0.93 | GCG (0.49) | GCGRP2RX1GCGKLK7GRIK1 | |
| SCHEMBL24118062 | 0.83 | IDO1 (0.54) | GCGRGCGKLK7POLBALDH1A1 | |
| SCHEMBL24117949 | 0.83 | IDO1 (0.53) | GCGPOLBALDH1A1L3MBTL1IDO1 | |
| SCHEMBL24117957 | 0.82 | GCGR (0.46) | GCGRGCG | |
| SCHEMBL24118068 | 0.82 | IDO1 (0.55) | KLK7POLBALDH1A1L3MBTL1IDO1 | |
| SCHEMBL24118064 | 0.82 | IDO1 (0.46) | GCGPOLBALDH1A1IDO1 | |
| SCHEMBL24118386 | 0.81 | MEN1 (0.42) | GCGPOLBALDH1A1L3MBTL1IDO1 | |
| SCHEMBL24118272 | 0.81 | MEN1 (0.44) | GCGPOLBALDH1A1RECQLIDO1 | |
| SCHEMBL24118073 | 0.81 | ALDH1A1 (0.46) | GCGPOLBALDH1A1L3MBTL1IDO1 | |
| SCHEMBL24118254 | 0.79 | FPR2 (0.48) | POLBALDH1A1RECQLCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | IDO1, IDO2, TPH1 | GCGR 3754/4885P2RX1 2238/4885GCG 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.